hrp0089p2-p383 | Thyroid P2 | ESPE2018

A Successful Switch Experience from High-dose PTU to MMI on Day 4 of Graves’ Thyroid Storm in a 14-Year-Old Girl

Shinohara Hiroyuki , Iwabuchi Atsushi , Yamada Akiko , Kai Tomomi , Kamoda Tomohiro

Background: The standard pharmacological treatment strategy of thyroid storm according to 2016 Japan Society of Pediatric Endocrinology Guideline. Although thiamazole (MMI) is recommended be used as the first choice in Graves’ disease, the effect of propylthiouracil (PTU) to block the conversion from T4 to T3 in peripheral tissues encourages clinicians to use against thyroid storm in its very early phase, and switch to MMI later. Nevertheless, the optimal timing of the sw...

hrp0084p3-1173 | Thyroid | ESPE2015

Avoidable Thiamazole-Induced Omphalomesenteric Duct Remnants: 20-Year Retrospective Study in Our Hospital

Shinohara Hiroyuki , Komori Koji , Hirobe Seiichi , Hasegawa Yukihiro

Background: Although thiamazole (MMI) is the first-line treatment for non-pregnant women with Graves’ disease, the teratogenic effects of this drug have been confirmed. Surgical anomalies known as ‘major MMI-related anomalies’ include omphalomesenteric duct remnants. This is a common difficulty when attempting to clarify whether there is any association between infrequent surgical anomalies and MMI exposure using data derived from women with Graves’ disease...